Vemurafenib is a V600E mutation-specific BRAF inhibitor that has been suggested as a treatment of metastatic disease.37In vitro studies of vemurafenib, dabrafenib, a MEK inhibitor (MEK162), and an AKT inhibitor (MK2206) showed that the combination of the latter two drugs had a synergistic effect in the inhibition of cell proliferation, but a BRAF wild-type and NRAS mutated cell line was irresponsive to BRAF inhibition.38 Here, BRAF is linked to metastatic neoplasm.